BCTX - BriaCell Therapeutics Corp.

3.76
-0.100   -2.660%

Share volume: 374,465
Last Updated: 03-09-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.20%

PREVIOUS CLOSE
CHG
CHG%
$3.86
-0.10
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
53%
Profitability 35%
Dept financing 38%
Liquidity 50%
Performance 75%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.23%
1 Month
-11.32%
3 Months
-66.76%
6 Months
-51.48%
1 Year
8.99%
2 Year
25.33%
Key data
Stock price
$3.76
P/E Ratio 
0.00
DAY RANGE
$3.68 - $3.96
EPS 
-$27.44
52 WEEK RANGE
$0.61 - $14.68
52 WEEK CHANGE
$2.73
MARKET CAP 
20.723 M
YIELD 
N/A
SHARES OUTSTANDING 
1.884 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-29-2025
NEXT EARNINGS DATE
06-13-2025
BETA 
1.98
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$239,912
AVERAGE 30 VOLUME 
$202,534
Company detail
CEO: William V. Williams
Region: US
Website: briacell.com
Employees: 8
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BriaCell Therapeutics Corp. engages in developing immunotherapies for the treatment of cancer. Lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors. Company also has a cooperative research and development agreement with the National Cancer Institute.

Recent news